Table 1. Top 10 most differentially regulated process for first and second line treatments in CAKI- 1 xenografts.
| Responders – sunitinib first line | |
|---|---|
| 1 | Translation_Translation initiation |
| 2 | Translation_Elongation-Termination |
| 3 | Translation_Elongation-Termination_test |
| 4 | Cell adhesion_Integrin-mediated cell-matrix adhesion |
| 5 | Cytoskeleton_Regulation of cytoskeleton rearrangement |
| 6 | Cell cycle_G2-M |
| 7 | Cell cycle_Mitosis |
| 8 | Cell adhesion_Platelet-endothelium-leucocyte interactions |
| 9 | Cell adhesion_Cell junctions |
| 10 | Cytoskeleton_Actin filaments |
| Progressive – sunitinib first line | |
| 1 | Development_Regulation of angiogenesis |
| 2 | Cell adhesion_Platelet-endothelium-leucocyte interactions |
| 3 | Cell adhesion_Attractive and repulsive receptors |
| 4 | Development_Neurogenesis_Synaptogenesis |
| 5 | Development_Neurogenesis_Axonal guidance |
| 6 | Proteolysis_ECM remodeling |
| 7 | Cytoskeleton_Actin filaments |
| 8 | Development_Blood vessel morphogenesis |
| 9 | Apoptosis_Anti-Apoptosis mediated by external signals via PI2K/AKT |
| 10 | Signal transduction_Androgen receptor signaling cross-talk |
| Everolimus second line following sunitinib progression | |
| 1 | Translation_Translation initiation |
| 2 | Cell cycle_Mitosis |
| 3 | Protein folding_response to unfolded proteins |
| 4 | Cytoskeleton_Regulation of cytoskeleton rearrangement |
| 5 | Translation_Elongation-Termination |
| 6 | Translation_Elongation-Termination_test |
| 7 | Cell adhesion_Cell junctions |
| 8 | Protein folding_Folding in normal condition |
| 9 | Cell adhesion_Integrin-mediated cell-matrix adhesion |
| 10 | Cell adhesion_Leukocyte chemotaxis |
| Axitinib second line following sunitinib progression | |
| 1 | Translation_Translation initiation |
| 2 | Proteolysis_Ubiquitin-proteasomal proteolysis |
| 3 | Cell cycle_Mitosis |
| 4 | Translation_Elongation-Termination |
| 5 | Translation_Elongation-Termination_test |
| 6 | Transcription_mRNA processing |
| 7 | Immune response_Antigen presentation |
| 8 | Cytoskeleton_Regulation of cytoskeleton rearrangement |
| 9 | Cell cycle_G2-M |
| 10 | Immune response_Phagosome in antigen presentation |
| Sorafenib second line following sunitinib progression | |
| 1 | Translation_Translation initiation |
| 2 | Proteolysis_Ubiquitin-proteasomal proteolysis |
| 3 | Transcription_mRNA processing |
| 4 | Cell cycle_Mitosis |
| 5 | Translation_Elongation-Termination |
| 6 | Translation_Elongation-Termination_test |
| 7 | Cell cycle_G1-S |
| 8 | Cell cycle_G2-M |
| 9 | Cytoskeleton_Regulation of cytoskeleton rearrangement |
| 10 | Protein folding_Folding in normal condition |
All 1.75 fold or greater (P < 0.05) gene expression changes for first-line sunitinib responders and progressive tumors as well as second-line sorafenib, axitinib, or everolimus were input into Metacore software. The top 10 network process maps were identified using Metacore's proprietary algorithm and ranked according to statistical significance via P values.